Iowanews Headlines

Endometrial Cancer – Pipeline Insight, 2026

DelveInsight’s “Endometrial Cancer – Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies developing over 55 pipeline drugs in the endometrial cancer landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Endometrial Cancer treatment landscape. Learn more about the evolving endometrial cancer pipeline today @ https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Endometrial Cancer Pipeline Report

• In March 2026, letrozole monotherapy failed to demonstrate noninferiority to chemotherapy followed by letrozole in patients with stage II–IV low-grade serous ovarian carcinoma at the SGO Annual Meeting.

• In February 2026, the SISTER trial reported that one-on-one peer support significantly increased treatment completion rates to 84% for Black women with high-risk endometrial cancer compared to 50% for those without support.

• In September 2025, the FDA hosted “Endometrial Cancer – Rising incidence. Rising innovation,” highlighting that 2025 estimates include over 69,000 new cases and nearly 14,000 deaths in the U.S..

• Interim Phase 1 data for mocertatug rezetecan showed rapid and deep responses in patients with recurrent or advanced endometrial cancer, with a confirmed ORR of 67% at a 4.8 mg/kg dose.

• Endometrial cancer is the most common gynecologic malignancy in developed countries, with incidence rising due to factors such as aging and obesity.

• The current pipeline features more than 55 drugs being advanced by over 50 global companies across all clinical stages.

• Selinexor, an oral exportin 1 inhibitor, is one of the most advanced pipeline candidates, currently in Phase III clinical trials for advanced or recurrent cases.

• Incyte Corporation is among the key players with advanced-stage drug candidates in Phase II clinical evaluation.

Download for updates and the latest revolution in Endometrial Cancer care @ Endometrial Cancer Market Insight, Epidemiology And Market Forecast

Endometrial Cancer Emerging Drugs Profile

Selinexor: Karyopharm Therapeutics

Selinexor is an oral selective inhibitor of nuclear export (SINE) compound that binds to and inhibits the nuclear export protein XPO1. It is currently being evaluated in Phase III clinical trials for the treatment of advanced or recurrent endometrial cancer. By blocking the export of tumor suppressor proteins from the nucleus, selinexor aims to restore normal cellular growth control mechanisms in cancer cells.

Abemaciclib: Eli Lilly and Company

Abemaciclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It is showing clinical benefit in Phase II trials for endometrial cancer, particularly when used in combination with hormonal therapies. The therapy targets the cell cycle to prevent tumor cell proliferation and is being explored as a potential new treatment option for advanced stages of the disease.

NP137: Netris Pharma

NP137 is a first-in-class monoclonal antibody designed to target netrin-1, a protein often overexpressed in various cancers, including endometrial cancer. By blocking the interaction between netrin-1 and its receptors, NP137 aims to induce apoptosis in tumor cells. It is currently undergoing clinical assessment to determine its efficacy and safety in patients with gynecologic malignancies.

For more information on the Endometrial Cancer Emerging Drugs Profile, download DelveInsight’s comprehensive Endometrial Cancer Pipeline Insight report.

The Endometrial Cancer Pipeline Report Provides

• Detailed insights about more than 50 companies developing therapies for Endometrial Cancer, including aggregate therapies developed by each.

• A comprehensive overview of different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development.

• Analysis of companies involved in targeted therapeutics development, including active and inactive projects.

• Drug profiles based on route of administration, target receptor, monotherapy or combination therapy, and molecular type.

• Detailed analysis of industry collaborations, licensing agreements, and financing details driving the market forward.

Learn more about Endometrial Cancer drug opportunities in our comprehensive pipeline report @ Endometrial Cancer Unmet Needs

Endometrial Cancer Companies and Competitive Landscape

There are over 50 key companies, including Karyopharm Therapeutics, Eli Lilly, Netris Pharma, Incyte Corporation, and others, developing therapies for Endometrial Cancer, with several candidates now in advanced Phase III and Phase II stages of clinical development.

DelveInsight’s Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Subcutaneous

• Intravenous

• Oral

• Intramuscular

Endometrial Cancer products have been categorized under various Molecule types such as:

• Small molecules

• Natural metabolites

• Monoclonal antibodies

Discover the latest advancements in Endometrial Cancer treatment by visiting our website. Stay informed @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Endometrial Cancer Pipeline Report

• Coverage: Global

• Endometrial Cancer Companies: Karyopharm Therapeutics, Eli Lilly, Netris Pharma, Incyte Corporation, and others.

• Endometrial Cancer Therapies: Selinexor, Abemaciclib, NP137, CT-0508, and others.

• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.

• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Table of Contents

1. Introduction

2. Executive Summary

3. Endometrial Cancer: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Endometrial Cancer – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Endometrial Cancer Key Companies

13. Endometrial Cancer Key Products

14. Endometrial Cancer Unmet Needs

15. Endometrial Cancer Market Drivers and Barriers

16. Endometrial Cancer Future Perspectives and Conclusion

17. Endometrial Cancer Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services